drugset / Trial / NCT04524884
Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate the efficacy and safety of the combination of Toripalimab and Surufatinib for Locally Advanced Thyroid Cancer.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2022-04-30
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 250 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |